Robert Florea, MD
Family Medicine · Columbus, OHNPI 1376723684
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,972 of the $9,196 with a category attached, or 86.7%. It is spread thinly across 35 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,400 and has fallen 98.0% since, to $49 in 2025. Among family medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 626 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Astrazeneca UK Limited$1K
- AstraZeneca$697
- Lilly USA, LLC$634
- Amarin Pharma, Inc.$592
- Nevro Corp.$564
- plus $4K from 29 others
Across 47 payments — averaging $20,133 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$405K
- Teva Pharmaceuticals USA, Inc.$238K
- Hikma Pharmaceuticals USA$187K
- Astrazeneca AB$46K
- GSK$33K
- BD$25K
- plus $11K from 1 others
What the payments were for
- Speaking & faculty fees$2373%
- Travel & lodging$91110%
- Food & beverage$7,97287%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 188 | $2,021 |
| Astrazeneca UK Limited | 6 | $1,054 |
| AstraZeneca | 38 | $697 |
| Lilly USA, LLC | 53 | $634 |
| Amarin Pharma, Inc. | 37 | $592 |
| Nevro Corp. | 10 | $564 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 53 | $525 |
| Biohaven Pharmaceutical Holding Company Ltd. | 35 | $413 |
| Redhill Biopharma Inc. | 29 | $332 |
| Daiichi Sankyo Inc. | 24 | $330 |
| Biohaven Pharmaceuticals, Inc. | 28 | $277 |
| Scilex Pharmaceuticals Inc. | 31 | $234 |
| Otsuka America Pharmaceutical, Inc. | 12 | $222 |
| Hikma Pharmaceuticals USA | 9 | $154 |
| Amgen | 10 | $145 |
| Sunovion Pharmaceuticals Inc. | 7 | $130 |
| Novo Nordisk | 7 | $105 |
| Jazz Pharmaceuticals Inc. | 7 | $102 |
| Boehringer Ingelheim | 5 | $81 |
| Indivior Inc. | 6 | $81 |
| Pfizer | 4 | $65 |
| GSK | 4 | $58 |
| MDD US Operations, LLC | 3 | $48 |
| Orexo US, Inc. | 3 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| BD | 1 | $37 |
| Abbott | 2 | $35 |
| Johnson & Johnson | 2 | $30 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Shionogi Inc | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,196 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 154 | $19,721 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $5,858 |
| Tizanidine Hcl | 51 | $1,215 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 103 | $1,160 |
| Gabapentin | 107 | $856 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 43 | $583 |
| Testosterone Cypionate | 21 | $534 |
| Alprazolam | 85 | $447 |
| Levothyroxine Sodium | 25 | $423 |
| Quetiapine Fumarate | 14 | $370 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $323 |
| Atorvastatin Calcium | 59 | $189 |
| Buspirone Hcl | 45 | $170 |
| Ibuprofen | 62 | $150 |
| Sumatriptan Succinate | 19 | $147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $154 | $19,721154 claims |
| Indivior Inc.Suboxone | $81 | $5,85814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Columbus
- Brian BeesleyColumbus$1.4M
- Kwabena OtengSpringdale$2M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
- David NeidhardtLima$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.